Compare Organon & Co. Common Stock (OGN) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs S&P500 ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while S&P500 ETF trades at $766.23 (market cap $821.11B). The key difference: S&P500 ETF is far larger — about 226.8× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and S&P500 ETF for 206 Days on average.
| OGN | SPY | |
|---|---|---|
Market Cap | $3.62B | $821.11B |
Volume | 2,892,999 | 25,825,560 |
Sector | Health | — |
52-Week High | $13.81 | $779.14 |
52-Week Low | $5.70 | $631.99 |
Typical Hold Time | 0 Days | 206 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SPY (SPDR S&P 500 ETF Trust) trades at $778.05, showing minimal daily movement with a slight decline of -0.02 (-0.0%). Technical indicators signal a bullish trend with strong moving average support, though oscillators remain neutral. The ETF maintains its position as the primary S&P 500 tracking fund with upcoming dividend distribution scheduled for October 2026.
The ETF's outlook remains tied to broader market performance with Wall Street monitoring earnings growth projections. Key risks include potential profit growth slowdown from 35% to 15% in 2027 and elevated market valuations. Current technical strength suggests near-term stability, but macroeconomic factors could drive volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
